BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IntelligentMDx to Present Development of Two CE-Marked Assays at 22nd Annual European Congress of Clinical Microbiology and Infectious Diseases


3/27/2012 2:16:11 PM

March 27, 2012, Cambridge, MA – IntelligentMDx (IMDx), a molecular diagnostic company that uses a proprietary bioinformatics platform that accelerates the development of PCR-based diagnostic testing solutions, will be presenting three posters at the 22nd annual European Congress of Clinical Microbiology and Infectious Diseases Meeting (ECCMID). The ECCMID meeting on March 31 – April 3, 2012 in London, UK, attracts more than 7,000 participants with expertise in infectious disease areas, including emerging infections, diagnosis, prevention, and treatment.

IMDx has designed, developed, and manufactured two CE-marked assays in the past year under a multi-year distribution agreement with Abbott. One CE-marked assay provides rapid and sensitive detection of toxigenic Clostridium difficile, while the second CE-marked assay provides for the detection of Vancomycin-resistant Enterococci. A third assay will be CE-marked later this year for the detection of Group B streptococcus. All three assays have been designed and validated to run on the Abbott m2000™ system, for fully automated, high-throughput diagnosis of these infectious diseases. The IMDx pipeline includes assays for detection of Herpes Simplex Virus 1 and 2, Influenza A/B and RSV, Epstein-Barr virus, BK virus, and additional assays targeting oncology, human genetics and companion diagnostics.

The three posters presented by Dr. Heinz Reiske, Manager of Research and Development at IMDx, will detail the technology used to develop the IMDx assays and present performance characteristics for each assay.

To view IMDx Posters at ECCMID, please visit:

Sunday, April 01, 2012, Poster Session III, 13:30 - 14:30, Spot P1381

Development of a high-throughput, rapid and sensitive molecular assay on the Abbott m2000 for detection of group B Streptococcus in antepartum and intrapartum women

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

Monday, April 02, 2012, Poster Session IV, 12:30 - 13:30, Spot P1659

A CE-marked automated molecular test on the Abbott m2000 for the detection of vancomycin resistance genes vanA and vanB most commonly found in vancomycin-resistant enterococci

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

Tuesday, April 03, 2012, Poster Session VI, 12:30 - 13:30, P 2268

A CE-marked DNA molecular assay on the Abbott m2000 for the detection of toxigenic and hypervirulent strains of C. difficile

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

* These products are intended for CE-marking and are not available for sale in the United States.

About IMDx

Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES